healthy individuals
Conditions
Interventions
Ingestion of study food (containing related ingredients 500mg ) for 12 weeks
Ingestion of study food (containing related ingredients 1000mg ) for 12 weeks
Ingestion of study food (containing related i
Sponsors
Miura Clinic, Medical Corporation Kanonkai
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Subjects of men and women aged 20 to 64 (2) Subjects who suffer from decreased motivation (3) Subjects who suffer from a drop in quality of sleep (4) Subjects who received a sufficient explanation of the purpose and contents of the study, an ability to consent, a volunteer who volunteered to participate with a good understanding and who agreed to participate in the study
Exclusion criteria
Exclusion criteria: (1) Subjects with liver disease, kidney disease, digestive system disease, heart disease, peripheral angiopathy and others who have a medical history that may affect the results of this test, or subjects who have a history of surgery (2) Subjects who show abnormal liver function and kidney function test values (3) Subjects who have a disease currently being treated (4) Subjects taking warfarin (5) Subjects with food and drug allergy (6) Subjects who have a history of mental disorder (such as depression) (7) Subjects who work at night or irregular working hours (8) Subjects with anemic symptoms (9) Those who do intense sports and subjects on diet (10) Subjects who can not quit the intake of health food (including food for FOSHU and Foods with Function Claims') and designated quasi-drugs during the test period (11) Subjects who are taking medication (OTC drugs, including prescription drugs) continuously (12) Those who consume too much alcohol or can not drink alcohol from 2 days before the test until the day Test subjects (13) Subjects who are pregnant or who are planning pregnancy or breastfeeding during the study period (14) Subjects participating in or planning to participate in other clinical trials at the start of this study (15) Subjects judged by the investigator as inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Subjective index Autonomic nerve activity index | — |
Secondary
| Measure | Time frame |
|---|---|
| Cortisol in saliva S-IgA in saliva Serum BDNF Uchida-Kraepelin test NK cell activity | — |
Countries
Japan
Contacts
Public ContactMakoto Terashima
Oneness Support Co., Ltd. Clinical Trial Division
Outcome results
None listed